January 26, 2024 07:14 AM ESTUpdated March 20, 04:17 AM
Manufacturing

Lon­za eyes rev­enue growth this year af­ter 2023 chal­lenges, plans to close sec­ond bi­o­log­ics site in a month

Anna Brown

News Reporter

Af­ter a year of nav­i­gat­ing “shift­ing mar­ket dy­nam­ics,” Lon­za re­port­ed on Fri­day it had a 7.9% sales rev­enue in­crease for 2023 com­pared to the pre­vi­ous …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times